Development of Monoclonal Antibodies
Monoclonal antibodies (mAbs) have revolutionized medicine and biotechnology, providing a targeted approach to treating diseases ranging from cancer to autoimmune disorders. These laboratory-made molecules are designed to mimic the immune system's ability to fight off harmful pathogens such as viruses and bacteria. The development of monoclonal antibodies involves a complex, multi-step process that integrates advanced biotechnology, molecular biology, and clinical research.
The concept of monoclonal antibodies was pioneered by Georges Köhler and César Milstein in the 1970s, for which they were awarded the Nobel Prize in 1984. They developed the hybridoma technology, which allows the production of identical antibody molecules. Hybridomas are created by fusing an antibodyproducing B-cell with an immortal myeloma cell, resulting in a hybrid cell line capable of producing large quantities of a single type of antibody.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
This breakthrough laid the groundwork for the production of monoclonal antibodies with high specificity, paving the way for their application in diagnostics, therapy, and research. Early applications were primarily diagnostic, but as technology advanced, therapeutic uses expanded dramatically.
The design of monoclonal antibodies begins with understanding the target molecule, often referred to as the antigen. This target is typically a protein associated with a disease, such as a receptor on cancer cells or a viral protein. Researchers first identify and characterize the antigen, often using high-throughput screening techniques and bioinformatics tools.
Once the target antigen is identified, animals such as mice are immunized with the antigen to stimulate the production of antibodies. The immune response generates a diverse pool of B-cells, each producing a unique antibody. These B-cells are then harvested and fused with myeloma cells to create hybridomas. The resulting hybridoma library is screened to identify clones producing antibodies with the desired specificity and affinity for the target antigen.
A significant limitation of early monoclonal antibodies was their immunogenicity in humans. Because they were derived from mouse proteins, patients often developed immune responses against the therapeutic antibody, reducing efficacy and causing adverse effects. To overcome this challenge, humanization techniques were developed.
Humanization involves modifying the genetic structure of the antibody to replace mouse-derived regions with human sequences, preserving the antibody's antigen-binding ability while reducing its immunogenicity. Advances in genetic engineering have allowed for the creation of fully human antibodies through the use of transgenic mice or phage display libraries, ensuring compatibility with the human immune system.
The production of monoclonal antibodies involves cultivating the selected hybridoma or recombinant cell line in large-scale bioreactors. These cells are cultured under controlled conditions to maximize antibody yield and quality. The culture medium is carefully optimized to provide nutrients and maintain pH, temperature, and oxygen levels conducive to cell growth
More in News
Clinical laboratories have always played an essential role in healthcare, but their influence now reaches far beyond test results. Every diagnosis, treatment plan and disease monitoring strategy depends on reliable laboratory data. What was once viewed primarily as a support function has become a critical contributor to clinical decision-making across the healthcare system.
That shift is changing how healthcare organizations invest in laboratory capabilities. Hospitals, health systems and independent laboratories face growing demand for faster turnaround times, greater testing capacity and increasingly complex diagnostic services. Rising rates of chronic disease, an aging population and advances in precision medicine continue to increase the volume and sophistication of laboratory testing.
The market reflects that momentum. Industry estimates place the global clinical laboratory services market at well over USD 250 billion, with steady growth expected throughout the coming decade. Demand continues to rise as healthcare providers rely more heavily on laboratory data to guide diagnosis, monitor treatment and improve patient outcomes.
“Precision medicine is creating new opportunities, but it also requires laboratories to develop specialized expertise and adopt more sophisticated technologies.”
North America remains one of the largest markets for clinical laboratory services, supported by advanced healthcare infrastructure, strong investment in diagnostics and continued innovation across laboratory technologies.
Technology Is Reshaping Laboratory Workflows
The modern clinical laboratory looks very different from the one that existed a decade ago. Automation has become a central part of laboratory operations. Routine processes that once required significant manual effort are increasingly handled by automated analyzers and robotic systems, allowing laboratory professionals to process higher test volumes while improving consistency.
Digital platforms are also changing how laboratories manage information. Laboratory information systems connect instruments, patient records and reporting workflows, giving clinicians faster access to results and reducing the risk of transcription errors.
Molecular diagnostics continue to expand the laboratory’s role. Advances in genetic testing, biomarker analysis and next-generation sequencing are helping clinicians identify diseases earlier and select therapies that are better matched to individual patients. Precision medicine is creating new opportunities, but it also requires laboratories to develop specialized expertise and adopt more sophisticated technologies.
Demand Continues to Grow Across Healthcare
Several long-term trends continue to shape the clinical laboratory market. Chronic diseases such as diabetes, cardiovascular disease and cancer require regular monitoring, increasing the demand for laboratory testing throughout a patient’s care journey.
Preventive healthcare is also becoming more common. Earlier diagnosis and routine screening programs are expanding testing volumes across primary care, specialty clinics and community health settings.
Public health preparedness remains another important priority. Lessons learned during recent global health emergencies reinforced the need for laboratory networks that can rapidly scale testing capacity while maintaining quality and accuracy.
Patients have become more engaged in their healthcare decisions as well. Many now expect quicker access to test results, greater transparency and more convenient testing options, encouraging laboratories to improve both efficiency and the patient experience.
What Healthcare Organizations Expect From Laboratory Partners.
Choosing a clinical laboratory is no longer based solely on testing capability. Healthcare organizations evaluate laboratories across a broader range of factors, including quality systems, regulatory compliance, turnaround times and the ability to support increasingly complex diagnostic requirements.
Integration has become equally important. Laboratory systems are expected to connect smoothly with electronic health records and other healthcare platforms, allowing clinicians to access results quickly and incorporate laboratory data into broader care decisions.
Scalability also plays an important role. Laboratories must be able to accommodate fluctuations in testing volumes without compromising quality or turnaround times. Workforce challenges continue to affect the sector. Many laboratories face shortages of experienced professionals while managing growing testing demand. Automation and digital technologies help address some of these pressures, yet skilled laboratory scientists remain essential for complex analysis, quality assurance and clinical interpretation.
Standardization presents another ongoing challenge. Large health systems often operate multiple laboratories with different equipment, workflows and reporting practices. Greater consistency across laboratory networks can improve efficiency while supporting more reliable clinical outcomes.
A Broader Role in the Future of Healthcare
Clinical laboratories are becoming increasingly central to modern healthcare. Advances in diagnostics, precision medicine and digital health will continue to expand the laboratory’s contribution to patient care. At the same time, healthcare organizations will expect laboratories to deliver faster results, greater accuracy and stronger data integration while maintaining rigorous quality standards.
Future investment is likely to focus on technologies that improve efficiency without sacrificing clinical confidence. Automation, molecular diagnostics and connected laboratory systems will continue to shape how testing services evolve over the coming years.
Clinical laboratories are no longer viewed simply as places where samples are analyzed. They have become trusted partners in diagnosis, disease management and clinical decision-making, helping healthcare providers deliver more informed care in an increasingly complex healthcare environment. ...Read more
Stem cell treatment centers are becoming more important in regions where patients need complex transplant services but must travel far from home for care. While public attention often focuses on regenerative medicine clinics, established stem cell treatment is most mature in areas such as blood cancers and serious blood disorders, where transplant programs require specialized hospital infrastructure.
A recent report from Australia described a campaign to establish a donor stem cell transplant service at Townsville University Hospital. The initiative aims to reduce the need for patients in North Queensland to travel to Brisbane for Total Body Irradiation before some stem cell transplants. This process can force patients and full-time carers to live away from home for months.
Where stem cell treatment is available can have a significant impact on the patient experience. Treatment often involves much more than a single clinical procedure, including pre-treatment conditioning, donor coordination, infection monitoring and an extended period of recovery. When these services are concentrated in major cities, patients and their families may have to travel long distances, take extended time away from work or home and manage the financial and personal strain that comes with receiving care far from their local community.
Treatment centers that expand access must still maintain high standards. A transplant program needs trained clinicians, laboratory support, inpatient capacity and emergency response systems. The complexity makes it different from office-based regenerative medicine offerings that may be marketed directly to consumers.
Health systems are therefore looking at hub-and-spoke models. A major center may manage advanced procedures, while regional providers support testing, follow-up care and patient education.
Expanding stem cell treatment services depends on people as much as infrastructure. A successful program requires experienced hematologists, transplant nurses, pharmacists and laboratory teams working together throughout the patient's care journey. Investing in equipment alone is not enough. Centers also need a coordinated model of care that can support patients before treatment, during therapy and throughout recovery.
For patients considering stem cell treatment, it should be clear whether a service is part of an established hospital program or an unapproved commercial offering. That distinction has become increasingly important as stem cell therapies attract wider attention. The FDA continues to advise consumers to avoid unapproved products made from human cells or tissues that are marketed online with broad treatment claims.
Stem cell treatment providers are increasingly following different paths. Hospital-based programs continue to build around approved therapies, multidisciplinary care and the clinical infrastructure needed to manage complex patients. At the same time, commercial clinics offering unapproved interventions are coming under closer regulatory and scientific scrutiny. As more treatment options emerge, centers that expand access without compromising clinical standards are likely to earn greater confidence from patients, physicians and regulators. ...Read more
Shortages in generic and biopharmaceutical medicines rarely begin as a single missed shipment. They build earlier, in product selection, dossier timing, plant readiness, inspection discipline and the handoffs between development teams and commercial supply. Healthcare systems and pharmaceutical partners face more than price exposure. A low-cost product that reaches the market late, produces incomplete regulatory documentation, strains sterile capacity or fails to sustain supply can create treatment gaps that procurement teams cannot correct once contracts are awarded.
The buying decision has moved beyond simple generic substitution. Sterile injectables and biosimilars carry tighter technical demands, while European launch planning adds country-by-country complexity in access policy, reimbursement, tender timing and route-to-market execution. Companies need development partners who can meet quality requirements while managing the economic pressures that drive the adoption of generics and biosimilars. This balance is difficult when discovery, clinical work, manufacturing and market entry are organised into disconnected supplier arrangements. Each handoff adds room for delay, unclear accountability, cost drift and late discovery of supply constraints.
Capacity alone does not settle the question. Value comes from operations that are audit-ready, disciplined in production planning and transparent throughout the supply chain. Customers benefit when manufacturing partners work within a shared planning rhythm. Procurement and commercial teams identify issues earlier when both sides align on demand, filing schedules, quality assessment and supplier risk. Close alignment prevents cost pressure from eroding quality standards or pushing corrective work past the launch calendar.
Portfolio strategy carries equal weight. A partner built solely around commodity generics may struggle when buyers need sterile dosage forms, peptides, complex injectables and biosimilars on a single development path. Breadth becomes a liability without disciplined product choice and clear market sequencing. Selective expansion is the stronger path, backed by investment in development capacity, credible regulatory preparation, experienced European staff and a realistic view of market entry. Europe is not one launch environment. It is a cluster of pricing rules, health system practices, tender calendars and local access requirements. The real question is whether a partner can connect scientific development, compliance preparation, manufacturing scale and commercial timing without leaving the buyer to manage every gap.
Evumed Limited’s model centres on pharmaceutical development and commercialisation as a whole. Its European headquarters in Cork, Ireland, covers regulatory affairs, quality, supply chain management and commercial support. Its strategic partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and Evumed Singapore, adds depth to its manufacturing and research and development. Its portfolio spans generic medicines, sterile injectables, peptides and biosimilars, backed by FDA-inspected facilities, expanding sterile production capacity and continued biosimilar investment. Development, manufacturing and market access work as a connected system, built to sustain supply and shorten the path to European market entry. ...Read more
Bioprocessing pump manufacturing is crucial in the biopharmaceutical, biotechnology, and industrial sectors. The industry continues to evolve due to various influencing factors, technological trends, and the increasing demand for precision in fluid handling. Manufacturers constantly refine their processes and equipment to meet industry requirements, adhere to strict regulatory standards, and improve efficiency. Automation and digitalization have revolutionized pump manufacturing.
The products require precise fluid management to maintain product integrity, pushing pump manufacturers to develop specialized solutions to ensure sterile and contamination-free operations. Pumps must handle various fluids, from aqueous solutions to highly viscous and shear-sensitive materials. The development of biocompatible, corrosion-resistant materials, such as stainless steel, PTFE, and single-use plastics, has allowed manufacturers to produce pumps that meet stringent hygiene and safety standards.
Modern bioprocessing facilities require pumps with advanced control systems, integrated sensors, and real-time monitoring to optimize fluid flow, minimize waste, and enhance efficiency. Automation reduces human intervention, lowering contamination risks and ensuring consistent production quality. Pumps must also comply with good manufacturing practices (GMP) and be easy to sterilize and clean, which ensures product safety and quality for manufacturers.
Future of Bioprocessing Efficiency
Companies seek energy-efficient pumps that reduce operational costs and environmental impact. Developing low-energy-consuming and recyclable pump components supports sustainability efforts while maintaining high performance. The bioprocessing pump industry is witnessing several trends that shape its future. Single-use pumps eliminate the need for extensive cleaning and sterilization, reducing downtime and cross-contamination risks. The pumps are particularly beneficial in biopharmaceutical applications, where sterility is paramount.
"Modern bioprocessing facilities require pumps with advanced control systems, integrated sensors, and real-time monitoring to optimize fluid flow, minimize waste, and enhance efficiency."
The rise of Industry 4.0 has led to the development of intelligent pumps equipped with IoT connectivity, real-time monitoring, and predictive maintenance capabilities. These features allow manufacturers to monitor pump performance remotely, detect issues early, and optimize maintenance schedules, reducing operational costs and increasing uptime. The demand for modular and scalable pump systems is growing. As bioprocessing facilities expand and adapt to new production requirements, manufacturers require flexible pump solutions that can be easily upgraded or modified.
Modular pump designs offer versatility and integrate easily into different bioprocessing setups. The shift toward continuous bioprocessing enhances efficiency, reduces production time, and minimizes variability. Pumps for constant operation must provide precise flow control, high reliability, and minimal downtime. These pumps are essential in various industries for fluid handling, ensuring product consistency and safety.
Pumps are essential for accurately transferring active pharmaceutical ingredients (APIs), buffers, and culture media in chromatography, filtration, and cell culture. In biotechnology, they facilitate cell cultivation, fermentation, and media preparation, ensuring optimal nutrient delivery and waste removal for ideal cell growth. Maintaining precise flow rates and minimizing shear stress is crucial for preserving cell viability. Additionally, bioprocessing pumps are used in the food and beverage industry to handle sensitive ingredients and flavorings.
Developments in Sanitary Pump Design for Bioprocessing Applications
Maintaining hygiene and preventing contamination is essential, making sanitary pumps with CIP (clean-in-place) and SIP (sterilize-in-place) capabilities indispensable in this sector. Industrial bioprocessing applications, such as biofuel production, utilize pumps to transfer feedstocks, enzymes, and fermentation products. The pumps must withstand corrosive and high-viscosity fluids while maintaining efficient performance over extended periods. Manufacturers face several challenges in designing and producing pumps that meet industry needs.
Some bioprocessing applications involve highly viscous, shear-sensitive, or foaming liquids that require specialized pump designs to maintain integrity and prevent degradation. Pumps used in the pharmaceutical and biotech industries must meet strict hygiene standards and be constructed from materials that comply with FDA, USP Class VI, and other regulatory requirements. Achieving compliance while maintaining cost-effectiveness requires careful material selection and design innovation. Sterility and contamination control pose additional difficulties.
Manufacturers must develop pumps with superior cleanability, minimal dead spaces, and compatibility with sterilization techniques such as gamma irradiation and autoclaving. Maintenance and longevity are critical concerns. Pumps must operate reliably over extended periods while minimizing downtime and maintenance requirements. The integration of advanced digital technologies presents opportunities and challenges.
Enhanced Efficiency and Compliance
Manufacturers utilize high-performance polymers, coated stainless steel, and elastomers with enhanced chemical and thermal stress resistance. The materials ensure longevity, compliance, and superior hygiene in bioprocessing applications. The adoption of automation and innovative monitoring technologies is transforming the industry. Pumps equipped with real-time sensors, automated flow control, and predictive maintenance capabilities improve process efficiency and reduce downtime. AI-driven analytics help manufacturers optimize performance, detect potential failures, and enhance overall reliability.
Single-use pump solutions are gaining popularity as they eliminate the need for cleaning validation and reduce contamination risks. These pumps offer cost-effective, flexible solutions for biopharmaceutical applications, particularly in small-batch production and personalized medicine. Collaboration between manufacturers, regulatory agencies, and research institutions is vital in advancing pump technology. By working together, stakeholders can develop standardized protocols, enhance regulatory frameworks, and drive innovation in bioprocessing pump manufacturing. ...Read more
